A113 TEDUGLUTIDE IN PATIENTS WITH ACTIVE CROHN’S DISEASE AND SHORT BOWEL SYNDROME

BACKGROUND: Patients with Crohn’s disease (CD) are at risk of surgery due to refractory or penetrating disease, which may result in short bowel syndrome (SBS) that requires parenteral nutrition (PN). Teduglutide is a GLP2 analogue that has been approved for the treatment of SBS although there has be...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Can Assoc Gastroenterol
Main Authors: Al Draiweesh, S, Ma, C, Gregor, J C, Rahman, A, Jairath, V
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Posters Of Distinction
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512651/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.112
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares